Chemokine receptor CCR5 antagonist Maraviroc: Medicinal chemistry and clinical applications

Current Topics in Medicinal Chemistry

Volumn 14, Issue 13, 2014, Pages 1504-1514

  Xu, Guoyan G ^a   Guo, Jia ^b   Wu, Yuntao ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Clinical study; HIV 1; HIV 2; Medicinal chemistry; Microbicide; SAR

Indexed keywords

BENZIMIDAZOLE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXYLAMINE DERIVATIVE; DAPIVIRINE; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; IMIDAZOPYRIDINE DERIVATIVE; LOPINAVIR; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MARAVIROC; MICROBICIDE; POTASSIUM CHANNEL HERG; RALTEGRAVIR; RANTES; RITONAVIR; TACROLIMUS; TROPANE DERIVATIVE; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL FUSION; CLINICAL STUDY; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; IMMUNE DEFICIENCY; MEDICINAL CHEMISTRY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STRUCTURE ACTIVITY RELATION; VIRAL TROPISM; VIRUS INHIBITION; VIRUS TRANSMISSION; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; METABOLISM; VIROLOGY; VIRUS REPLICATION;

CCR5 RECEPTOR ANTAGONISTS; CYCLOHEXANES; DRUG DISCOVERY; HIV; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; VIRUS REPLICATION;

EID: 84907172237     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140827143745     Document Type: Article

References (63)

1. Klatzmann, D.; Champagne, E.; Chamaret, S.; Gruest, J.; Guetard, D.; Hercend, T.; Gluckman, J. C.; Montagnier, L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature, 1984, 312(5996), 767-768.
2. Ashorn, P. A.; Berger, E. A.; Moss, B. Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J. Virol., 1990, 64(5), 2149-2156.
3. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996, 272(5263), 872-877.
4. Cocchi, F.; DeVico, A. L.; Garzino-Demo, A.; Arya, S. K.; Gallo, R. C.; Lusso, P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science, 1995, 270(5243), 1811-1815.
5. Alkhatib, G.; Combadiere, C.; Broder, C. C.; Feng, Y.; Kennedy, P. E.; Murphy, P. M.; Berger, E. A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophagetropic HIV-1. Science, 1996, 272(5270), 1955-1958.
6. Choe, H.; Farzan, M.; Sun, Y.; Sullivan, N.; Rollins, B.; Ponath, P. D.; Wu, L.; Mackay, C. R.; LaRosa, G.; Newman, W.; Gerard, N.; Gerard, C.; Sodroski, J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell, 1996, 85(7), 1135-1148.
7. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R. E.; Hill, C. M.; Davis, C. B.; Peiper, S. C.; Schall, T. J.; Littman, D. R.; Landau, N. R. Identification of a major co-receptor for primary isolates of HIV-1. Nature, 1996, 381(6584), 661-666.
8. Doranz, B. J.; Rucker, J.; Yi, Y.; Smyth, R. J.; Samson, M.; Peiper, S. C.; Parmentier, M.; Collman, R. G.; Doms, R. W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell, 1996, 85(7), 1149-1158.
9. Dragic, T.; Litwin, V.; Allaway, G. P.; Martin, S. R.; Huang, Y.; Nagashima, K. A.; Cayanan, C.; Maddon, P. J.; Koup, R. A.; Moore, J. P.; Paxton, W. A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature, 1996, 381(6584), 667-673.
10. Dean, M.; Carrington, M.; Winkler, C.; Huttley, G. A.; Smith, M. W.; Allikmets, R.; Goedert, J. J.; Buchbinder, S. P.; Vittinghoff, E.; Gomperts, E.; Donfield, S.; Vlahov, D.; Kaslow, R.; Saah, A.; Rinaldo, C.; Detels, R.; O'Brien, S. J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science, 1996, 273(5283), 1856-1862.
11. Wood, A.; Armour, D. The discovery of the CCR5 receptor antagonist, UK-427, 857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem., 2005, 43(239-271).
12. Meanwell, N. A.; Kadow, J. F. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr. Opin. Investig. Drugs, 2007, 8(8), 669-681.
13. Dorr, P.; Perros, M. CCR5 inhibitors in HIV-1 therapy. Expert Opin. Drug Discov., 2008, 3(11), 1345-1361.
14. Gulick, R. M.; Lalezari, J.; Goodrich, J.; Clumeck, N.; DeJesus, E.; Horban, A.; Nadler, J.; Clotet, B.; Karlsson, A.; Wohlfeiler, M.; Montana, J. B.; McHale, M.; Sullivan, J.; Ridgway, C.; Felstead, S.; Dunne, M. W.; van der Ryst, E.; Mayer, H. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med., 2008, 359(14), 1429-1441.
15. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother., 2005, 49(11), 4721-4732.
16. Price, D. A.; Armour, D.; de Groot, M.; Leishman, D.; Napier, C.; Perros, M.; Stammen, B. L.; Wood, A. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg. Med. Chem. Lett., 2006, 16(17), 4633-4637.
17. Price, D. A.; Armour, D.; de Groot, M.; Leishman, D.; Napier, C.; Perros, M.; Stammen, B. L.; Wood, A. Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV. Curr. Top. Med. Chem., 2008, 8(13), 1140-1151.
18. Barber, C. G.; Blakemore, D. C.; Chiva, J. Y.; Eastwood, R. L.; Middleton, D. S.; Paradowski, K. A. 1-Amido-1-phenyl-3-piperidinylbutanes-CCR5 antagonists for the treatment of HIV. Part 1. Bioorg. Med. Chem. Lett., 2009, 19(4), 1075-1079.
19. Lemoine, R. C.; Petersen, A. C.; Setti, L.; Baldinger, T.; Wanner, J.; Jekle, A.; Heilek, G.; deRosier, A.; Ji, C.; Rotstein, D. M. Evaluation of a 3-amino-8-azabicyclo[3. 2. 1]octane replacement in the CCR5 antagonist maraviroc. Bioorg. Med. Chem. Lett., 2010, 20(5), 1674-1676.
20. Ernst, J.; Dahl, R.; Lum, C.; Sebo, L.; Urban, J.; Miller, S. G.; Lundstrom, J. Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists. Bioorg. Med. Chem. Lett., 2008, 18(4), 1498-1501.
21. Coakley, E.; Petropoulos, C. J.; Whitcomb, J. M. Assessing chemokine co-receptor usage in HIV. Curr. Opin. Infect. Dis., 2005, 18(1), 9-15.
22. Kazmierski, W. M.; Aquino, C.; Chauder, B. A.; Deanda, F.; Ferris, R.; Jones-Hertzog, D. K.; Kenakin, T.; Koble, C. S.; Watson, C.; Wheelan, P.; Yang, H.; Youngman, M. Discovery of bioavailable 4, 4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1. J. Med. Chem., 2008, 51(20), 6538-6546.
23. Duan, M.; Aquino, C.; Ferris, R.; Kazmierski, W. M.; Kenakin, T.; Koble, C.; Wheelan, P.; Watson, C.; Youngman, M. [2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring. Bioorg. Med. Chem. Lett., 2009, 19(6), 1610-1613.
24. Kazmierski, W. M.; Anderson, D. L.; Aquino, C.; Chauder, B. A.; Duan, M.; Ferris, R.; Kenakin, T.; Koble, C. S.; Lang, D. G.; McIntyre, M. S.; Peckham, J.; Watson, C.; Wheelan, P.; Spaltenstein, A.; Wire, M. B.; Svolto, A.; Youngman, M. Novel 4, 4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. J. Med. Chem., 2011, 54(11), 3756-3767.
25. Duan, M.; Aquino, C.; Dorsey, G. F. Jr.; Ferris, R.; Kazmierski, W. M. 4, 4-Disubstituted cyclohexylamine based CCR5 chemokine receptor antagonists as anti-HIV-1 agents. Bioorg. Med. Chem. Lett., 2009, 19(17), 4988-4992.
26. Abel, S.; Russell, D.; Whitlock, L. A.; Ridgway, C. E.; Nedderman, A. N.; Walker, D. K. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br. J. Clin. Pharmacol., 2008, 65 Suppl 1, 60-67.
27. Chan, P. L.; Weatherley, B.; McFadyen, L. A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br. J. Clin. Pharmacol., 2008, 65 Suppl 1, 76-85.
28. Stupple, P. A.; Batchelor, D. V.; Corless, M.; Dorr, P. K.; Ellis, D.; Fenwick, D. R.; Galan, S. R.; Jones, R. M.; Mason, H. J.; Middleton, D. S.; Perros, M.; Perruccio, F.; Platts, M. Y.; Pryde, D. C.; Rodrigues, D.; Smith, N. N.; Stephenson, P. T.; Webster, R.; Westby, M.; Wood, A. An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4, 5, 6, 7-tetrahydr o-1H-imidazo[4, 5-c]pyridin-1-yl)-8-azabicyclo[3. 2. 1]oct-8-yl]propyl}acetamide (PF-232798). J. Med. Chem., 2010, 54(1), 67-77.
29. Liu, Y.; Zhou, E.; Yu, K.; Zhu, J.; Zhang, Y.; Xie, X.; Li, J.; Jiang, H. Discovery of a novel CCR5 antagonist lead compound through fragment assembly. Molecules, 2008, 13(10), 2426-2441.
30. Emmelkamp, J. M.; Rockstroh, J. K. Maraviroc, risks and benefits: a review of the clinical literature. Expert Opin. Drug Saf., 2008, 7(5), 559-569.
31. Gilliam, B. L.; Riedel, D. J.; Redfield, R. R. Clinical use of CCR5 inhibitors in HIV and beyond. J. Transl. Med., 2011, 9 Suppl 1, S9.
32. Haqqani, A. A.; Tilton, J. C. Entry inhibitors and their use in the treatment of HIV-1 infection. Antiviral Res., 2013, 98(2), 158-170.
33. Henrich, T. J.; Kuritzkes, D. R. HIV-1 entry inhibitors: recent development and clinical use. Curr. Opin. Virol., 2013, 3(1), 51-57.
34. Gutierrez, F.; Rodriguez, J. C.; Garcia, F.; Poveda, E. [Methods for determination of HIV tropism and their clinical use]. Enferm. Infecc. Microbiol. Clin., 2012, 29 Suppl 5, 45-50.
35. Genebat, M.; Pulido, I.; Romero-Sanchez, M. C.; Gonzalez-Serna, A.; Ferrando-Martinez, S.; Machmach, K.; Pacheco, Y. M.; Munoz-Fernandez, M. A.; Ruiz-Mateos, E.; Leal, M. Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment. Antiviral Res., 2012, 95(3), 207-211.
36. Calcagno, A.; Nozza, S.; Gonzalez de Requena, D.; Galli, A.; D'Avolio, A.; Simiele, M.; Chiappetta, S.; Di Perri, G.; Lazzarin, A.; Bonora, S. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. J. Antimicrob. Chemother., 2013, 68(7), 1686-1688.
37. Mora-Peris, B.; Croucher, A.; Else, L. J.; Vera, J. H.; Khoo, S.; Scullard, G.; Back, D.; Winston, A. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. J. Antimicrob. Chemother., 2013, 68(6), 1348-1353.
38. Goodrich JM; Saag M; van der Ryst E, et. al. 48-week safety and efficacy of maraviroc, a novel CCR5 antagonist in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced patients infected with dual/mixed-tropic HIV-1 [abstract LB-2]. 45th Annual Meeting of the Infectious Diseases Society of America; San Diego, California October 4-7, 2007.
39. Fatkenheuer, G.; Nelson, M.; Lazzarin, A.; Konourina, I.; Hoepelman, A. I.; Lampiris, H.; Hirschel, B.; Tebas, P.; Raffi, F.; Trottier, B.; Bellos, N.; Saag, M.; Cooper, D. A.; Westby, M.; Tawadrous, M.; Sullivan, J. F.; Ridgway, C.; Dunne, M. W.; Felstead, S.; Mayer, H.; van der Ryst, E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med., 2008, 359(14), 1442-1455.
40. Hardy, W. D.; Gulick, R. M.; Mayer, H.; Fatkenheuer, G.; Nelson, M.; Heera, J.; Rajicic, N.; Goodrich, J. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J. Acquir. Immune. Defic. Syndr., 2010, 55(5), 558-564.
41. Furtado, J.; Madruga, J. V.; Bicudo, E. L.; da Eira, M.; Lopes, M. I.; Netto, E. M.; Santini-Oliveira, M.; Leite, O. H.; Machado, A. A.; Tupinambas, U.; de Andrade Neto, J. L.; Lima, M. P.; Pedro Rde, J.; Miranda, A. F.; Lewi, D. S.; Santos, B. R.; Portsmouth, S.; Wajsbrot, D. B.; Cassoli, L. M. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study. AIDS Res. Hum. Retroviruses, 2013, 29(9), 1203-1210.
42. Antoniou, T.; Smith, G.; Su, D.; Raboud, J. M.; Lee, D.; Kovacs, C.; Brunetta, J.; Fletcher, D.; Crouzat, F.; Loutfy, M. Immunologic Effectiveness of Maraviroc-and Raltegravir-Containing Regimens (R+M+) versus Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M-). J. Int. Assoc. Physicians AIDS Care (Chic), 2012, 11(3), 192-197.
43. Degli Antoni, A.; Weimer, L. E.; Manfredi, R.; Fragola, V.; Ferrari, C. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use. West Indian Med. J., 2013, 61(9), 932-936.
44. Leonard, J. T.; Roy, K. The HIV entry inhibitors revisited. Curr. Med. Chem., 2006, 13(8), 911-934.
45. MacArthur, R. D.; Novak, R. M. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis., 2008, 47(2), 236-241.
46. Westby, M.; Smith-Burchnell, C.; Mori, J.; Lewis, M.; Mosley, M.; Stockdale, M.; Dorr, P.; Ciaramella, G.; Perros, M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol., 2007, 81(5), 2359-2371.
47. Bonjoch, A.; Pou, C.; Perez-Alvarez, N.; Bellido, R.; Casadella, M.; Puig, J.; Noguera-Julian, M.; Clotet, B.; Negredo, E.; Paredes, R. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. J. Antimicrob. Chemother., 2013, 68(6), 1382-1387.
48. Dufty, N. E.; Gilleran, G.; Hawkins, D.; Else, L. J.; Taylor, S. Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma. J. Antimicrob. Chemother., 2012, 68(4), 972-974.
49. Cipriani, S.; Francisci, D.; Mencarelli, A.; Renga, B.; Schiaroli, E.; D'Amore, C.; Baldelli, F.; Fiorucci, S. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation, 2013, 127(21), 2114-2124.
50. Diaz-Delfin, J.; Domingo, P.; Giralt, M.; Villarroya, F. Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation. Cytokine, 2013, 61(3), 808-815.
51. Gruber, V. A.; Rainey, P. M.; Lum, P. J.; Beatty, G. W.; Aweeka, F. T.; McCance-Katz, E. F. Interactions between Alcohol and the HIV Entry Inhibitor Maraviroc. J. Int. Assoc. Provid AIDS Care, 2013.
52. Visseaux, B.; Charpentier, C.; Hurtado-Nedelec, M.; Storto, A.; Antoine, R.; Peytavin, G.; Damond, F.; Matheron, S.; Brun-Vezinet, F.; Descamps, D. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors. Antimicrob. Agents Chemother., 2011, 56(1), 137-139.
53. Borrego, P.; Calado, R.; Marcelino, J. M.; Bartolo, I.; Rocha, C.; Cavaco-Silva, P.; Doroana, M.; Antunes, F.; Maltez, F.; Caixas, U.; Barroso, H.; Taveira, N. Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir. Ther., 2012, 17(3), 565-570.
54. Stegmann, S.; Manea, M. E.; Charpentier, C.; Damond, F.; Karmochkine, M.; Laureillard, D.; Si-Mohamed, A.; Weiss, L.; Piketty, C. Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. J. Clin. Virol., 2009, 47(1), 79-81.
55. Armstrong-James, D.; Stebbing, J.; Scourfield, A.; Smit, E.; Ferns, B.; Pillay, D.; Nelson, M. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res., 2010, 86(2), 224-226.
56. Caixas, U.; Ferreira, J.; Marinho, A. T.; Faustino, I.; Grilo, N. M.; Lampreia, F.; Germano, I.; Monteiro, E. C.; Pereira, S. A. Longterm maraviroc use as salvage therapy in HIV-2 infection. J. Antimicrob. Chemother., 2012, 67(10), 2538-2539.
57. Veazey, R. S.; Ketas, T. J.; Dufour, J.; Moroney-Rasmussen, T.; Green, L. C.; Klasse, P. J.; Moore, J. P. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J. Infect. Dis., 2010, 202(5), 739-744.
58. Malcolm, R. K.; Forbes, C. J.; Geer, L.; Veazey, R. S.; Goldman, L.; Klasse, P. J.; Moore, J. P. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J. Antimicrob. Chemother., 2012, 68(3), 678-683.
59. Neff, C. P.; Kurisu, T.; Ndolo, T.; Fox, K.; Akkina, R. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One, 2011, 6(6), e20209.
60. Malcolm, R. K.; Veazey, R. S.; Geer, L.; Lowry, D.; Fetherston, S. M.; Murphy, D. J.; Boyd, P.; Major, I.; Shattock, R. J.; Klasse, P. J.; Doyle, L. A.; Rasmussen, K. K.; Goldman, L.; Ketas, T. J.; Moore, J. P. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob. Agents Chemother., 2012, 56(5), 2251-2258.
61. Fetherston, S. M.; Boyd, P.; McCoy, C. F.; McBride, M. C.; Edwards, K. L.; Ampofo, S.; Malcolm, R. K. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Eur. J. Pharm. Sci., 2012, 48(3), 406-415.
62. Cordoba, E. V.; Arnaiz, E.; De La Mata, F. J.; Gomez, R.; Leal, M.; Pion, M.; Munoz-Fernandez, M. A. Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro. AIDS, 2013.
63. Barouch, D. H.; Klasse, P. J.; Dufour, J.; Veazey, R. S.; Moore, J. P. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. P. Natl. Acad. Sci. USA., 2012, 109(22), 8694-8698.